AKYA vs. QTRX, SENS, NAUT, KEQU, FEIM, SEER, OPTX, CLIR, MASS, and OWLT
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Quanterix (QTRX), Senseonics (SENS), Nautilus Biotechnology (NAUT), Kewaunee Scientific (KEQU), Frequency Electronics (FEIM), Seer (SEER), Syntec Optics (OPTX), ClearSign Technologies (CLIR), 908 Devices (MASS), and Owlet (OWLT). These companies are all part of the "measuring and control equipment" industry.
Akoya Biosciences vs.
Akoya Biosciences (NASDAQ:AKYA) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
In the previous week, Quanterix had 2 more articles in the media than Akoya Biosciences. MarketBeat recorded 7 mentions for Quanterix and 5 mentions for Akoya Biosciences. Akoya Biosciences' average media sentiment score of 1.53 beat Quanterix's score of 0.10 indicating that Akoya Biosciences is being referred to more favorably in the media.
Quanterix has a net margin of -30.71% compared to Akoya Biosciences' net margin of -66.77%. Quanterix's return on equity of -11.52% beat Akoya Biosciences' return on equity.
Quanterix has higher revenue and earnings than Akoya Biosciences. Quanterix is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks.
Quanterix received 235 more outperform votes than Akoya Biosciences when rated by MarketBeat users. Likewise, 61.56% of users gave Quanterix an outperform vote while only 60.71% of users gave Akoya Biosciences an outperform vote.
Akoya Biosciences currently has a consensus target price of $5.43, suggesting a potential upside of 113.72%. Quanterix has a consensus target price of $23.25, suggesting a potential upside of 88.26%. Given Akoya Biosciences' higher probable upside, research analysts clearly believe Akoya Biosciences is more favorable than Quanterix.
Akoya Biosciences has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
79.4% of Akoya Biosciences shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 7.3% of Akoya Biosciences shares are owned by insiders. Comparatively, 6.9% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Quanterix beats Akoya Biosciences on 13 of the 17 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:AKYA) was last updated on 1/6/2025 by MarketBeat.com Staff
Free AKYA Stock Alerts